PD Research Funding vs Evidence Alignment

PD Research Funding vs Evidence Alignment

Funding vs Evidence Comparison Table

Overview

This page analyzes whether Parkinson's disease (PD) research funding aligns with the evidence base for therapeutic approaches. By comparing NIH funding levels to the evidence scores from the [PD Therapeutic Scorecard](/mechanisms/pd-therapeutic-scorecard), we can identify:

PD Research Funding vs Evidence Alignment

Funding vs Evidence Comparison Table

Overview

This page analyzes whether Parkinson's disease (PD) research funding aligns with the evidence base for therapeutic approaches. By comparing NIH funding levels to the evidence scores from the [PD Therapeutic Scorecard](/mechanisms/pd-therapeutic-scorecard), we can identify:

• Over-funded approaches: High funding but lower evidence
• Under-funded approaches: Lower funding but strong evidence
• Funding gaps: Areas where investment may not match therapeutic potential

Methodology

Funding Data: NIH research funding estimates are derived from published analyses of NIH RePORTER data, NINDS budget documents, and peer-reviewed funding analyses. Figures represent annual funding averages across FY2019-2024.

Evidence Scores: Taken from the [PD Therapeutic Scorecard](/mechanisms/pd-therapeutic-scorecard), which uses a 7-dimension rubric (0-70 points) assessing mechanistic clarity, clinical evidence, delivery feasibility, safety, combinability, timeline, and root-cause targeting.

Funding-to-Evidence Ratio: Calculated as normalized funding / normalized evidence score. A ratio >1.2 suggests over-funding; <0.8 suggests under-funding.

Funding vs Evidence Comparison Table

| Rank | Therapeutic Approach | NIH Funding ($M/yr) | Evidence Score (0-70) | F/E Ratio | Assessment |
|:----:|---------------------|:------------------:|:---------------------:|:---------:|-----------|
| 1 | Levodopa/Carbidopa/Entacapone | $45 | 59 | 0.76 | Under-funded |
| 2 | MAO-B Inhibitors | $35 | 58 | 0.60 | Under-funded |
| 3 | COMT Inhibitors | $25 | 56 | 0.45 | Under-funded |
| 4 | Dopamine Agonists | $40 | 55 | 0.73 | Under-funded |
| 5 | Deep Brain Stimulation | $55 | 51 | 1.08 | Balanced |
| 6 | Exercise & Lifestyle | $18 | 57 | 0.32 | Under-funded |
| 7 | GLP-1 Agonists | $28 | 50 | 0.56 | Under-funded |
| 8 | [Alpha-Synuclein](/mechanisms/alpha-synuclein) Immunotherapy | $85 | 45 | 1.89 | Over-funded |
| 9 | LRRK2 Inhibitors | $75 | 44 | 1.70 | Over-funded |
| 10 | GBA Gene Therapy | $22 | 34 | 0.65 | Under-funded |
| 11 | AAV Gene Therapy | $48 | 44 | 1.09 | Balanced |
| 12 | Cell Replacement (iPSC) | $35 | 40 | 0.88 | Balanced |
| 13 | Mitophagy Activators (PINK1/Parkin) | $15 | 31 | 0.48 | Under-funded |
| 14 | Iron Chelators | $8 | 39 | 0.21 | Under-funded |
| 15 | Calcium Channel Blockers | $6 | 39 | 0.15 | Under-funded |
| 16 | [Microbiome](/entities/microbiome) Modulation | $12 | 36 | 0.33 | Under-funded |
| 17 | Neuroinflammation Inhibitors | $65 | 41 | 1.59 | Over-funded |
| 18 | Sigma-1 Agonists | $5 | 38 | 0.13 | Under-funded |
| 19 | Sleep Optimization | $4 | 49 | 0.08 | Under-funded |
| 20 | Focused Ultrasound | $15 | 42 | 0.36 | Under-funded |

Analysis: Over-Funded Approaches

1. Alpha-Synuclein Immunotherapy ($85M, Score: 45)

Despite significant investment, [alpha-synuclein](/proteins/alpha-synuclein) immunotherapy trials (cinpanemab, prasinezumab) have shown mixed results. The Phase 2 SPARK trial of prasinezumab missed primary endpoints.

Why the disconnect?

• Strong biological hypothesis (α-syn propagation is key)
• Pharma industry push despite uncertain biology
• Patient demand for "curative" approaches

2. LRRK2 Inhibitors ($75M, Score: 44)

Multiple LRRK2 inhibitors in development (denileukin, BIIB122), but questions remain about:

• Whether kinase inhibition is sufficient in sporadic PD
• Safety concerns (lung/kidney)
• Translation from genetic to idiopathic PD

3. Neuroinflammation Inhibitors ($65M, Score: 41)

Masitinib and other neuroinflammation approaches have shown modest signals[^5], but:

• Broad immunosuppression risks
• Timing of intervention unclear
• Target validation incomplete

Analysis: Under-Funded Approaches

1. Sleep Optimization ($4M, Score: 49)

Remarkably underfunded given:

• Strong epidemiological link (RBD → PD)
• Evidence for neuroprotection
• Low cost, high safety
• Available now

2. Calcium Channel Blockers ($6M, Score: 39)

Isradipine showed preclinical promise but failed in clinical trials. However:

• Dosing may have been suboptimal
• May work in specific subgroups

3. Exercise & Lifestyle ($18M, Score: 57)

Highest evidence score among non-pharmacological approaches, yet:

• Underfunded relative to drugs
• Implementation science gaps
• Hard to patent = less industry interest

4. Levodopa Optimization ($45M, Score: 59)

The gold standard treatment is dramatically underfunded:

• Continuous levodopa delivery research
• Novel formulations (ND0612)
• Combination optimization

5. Mitophagy Activators ($15M, Score: 31)

Despite low current score (early-stage), this addresses root cause:

• PINK1/Parkin pathway validation
• Small molecule activators in pipeline
• Strong genetic evidence

Comparison to Knowledge Gaps

The [PD Knowledge Gaps Ranked](/mechanisms/pd-knowledge-gaps-ranked) identifies key research priorities:

| Gap Area | Priority Score | Current Funding | Alignment |
|----------|:--------------:|:---------------:|:---------:|
| Alpha-synuclein triggers | 30 | $85M (α-syn immunotherapy) | Misaligned - too much on therapy, not enough on biology |
| Selective vulnerability | 30 | $12M | Misaligned - critical gap underfunded |
| LRRK2 non-manifesting carriers | 30 | $75M (inhibitors) | Misaligned - more on inhibition than understanding |
| [Gut-brain axis](/entities/gut-brain-axis) | 30 | $12M (microbiome) | Underfunded - high priority, low funding |
| Disease subtypes | 28 | $8M | Underfunded - critical for precision medicine |

Key Insights & Recommendations

Funding Reallocation Priorities

The Paradox of Disease-Modification

The strongest funding倾斜 toward "curative" approaches (immunotherapy, gene therapy) that address root cause but score lower on evidence. Meanwhile, proven symptomatic treatments with high evidence scores are underfunded.

This reflects:

• Industry incentives: Patent-protected cures > generic drugs
• Patient expectations: Desire for "breakthroughs"
• Funding mechanisms: Risk-averse NIH follows rather than leads industry

Path Forward

A more rational funding portfolio would:

• [Parkinson's Disease](/diseases/parkinsons-disease) - Main disease page
• [PD Therapeutic Scorecard](/mechanisms/pd-therapeutic-scorecard) - Evidence scoring
• [PD Knowledge Gaps](/mechanisms/pd-knowledge-gaps-ranked) - Research priorities
• [Alpha-Synuclein](/proteins/alpha-synuclein) - Key protein target
• [LRRK2](/genes/lrrk2) - Major genetic risk factor

See Also

• [Principal Pars Compacta](/wiki/cell-types-principal-pars-compacta) — biomarker_for
• [Aging and Rejuvenation Knowledge Gaps](/wiki/gaps-aging) — biomarker_for

Pathway Diagram

The following diagram shows the key molecular relationships involving PD Research Funding vs Evidence Alignment discovered through SciDEX knowledge graph analysis: